Greenville, United States
Kiyatec Inc. is at the forefront of revolutionizing cancer care with its distinctive approach of predicting patient-specific responses to therapies even before treatment starts. Founded in 2010, this U.S.-based biotechnology company integrates living tumor cells from patients to develop functional 3D models, thereby identifying effective treatments quickly and facilitating truly personalized medicine.
The company's methods have undergone validation through collaborations with leading cancer institutions, top-tier pharmaceutical firms, and the National Cancer Institute (NCI). This gives Kiyatec credibility in its mission. Ongoing robust clinical trials aim to demonstrate the efficacy and scalability of their portfolio, ensuring their approach aligns with both current and future therapies.
In May 2023, Kiyatec secured a $18.00M Series C investment from the Brain Tumor Investment Fund. This capital infusion is expected to propel the commercialization of their innovative solutions and catalyze further development and market penetration.
